TAG:
the human genome project
New Company Tracks Details and Prices For 60,000 Molecular and Genetic Tests
By Joseph Burns | From the Volume XXIII, No. 1 – January 19, 2016 Issue
CEO SUMMARY: Advances in the speed, accuracy, and cost of next-generation gene sequencing making it possible for clinical labs to create thousands of new tests. How many new tests? NextGxDx, an information technology company, says the nation’s clinical laboratories are introducing new m…
Medicare Ends Coverage for Genetic Drug-Sensitivity Tests
By Joseph Burns | From the Volume XXII NO. 9 – June 22, 2015 Issue
CEO SUMMARY: Medicare’s decision to cease covering many pharmacogenomic tests puts as many as 19 million Americans who have genetic variations affecting their response to medications at risk. These medications are commonly prescribed for patients with cardiovascular disease, pain…
Medicare Ends Coverage for Some Pharmacogenomic Testing
By Mary Van Doren | From the Volume XXII NO. 9 – June 22, 2015 Issue
WHAT THE FEDERAL GOVERNMENT giveth with one hand, it will often taketh away with the other hand. It might be argued that this is true of federal support of pharmacogenomic testing — particularly for those tests clinical labor…
May 23, 2011 “Intelligence: Late Breaking Lab News”
By Robert Michel | From the Volume XVIII No. 7 – May 23, 2011 Issue
The first sequencing of the whole human genome back in 2000 unleashed a tidal wave of research and development. Recently, Fast Company Magazine quantified the dollar impact of the Human Genome Project and now says it totals $800 billion! Their reporter communicates this so succinctly that TH…
Whole Genome Sequencing: Is It Ready for Prime Time?
By Robert Michel | From the Volume XVII No. 16 – November 15, 2010 Issue
CEO Summary: Pathologists at Beth Israel Deaconess Medical Center in Boston, Massachusetts, in a collaboration with GenomeQuest, Inc., will produce whole human genome sequences of patient tumors and other specimens. These whole genome sequences will be studied to learn what diagn…
“Primary-Care Pathology” One Goal at Beth Israel
By Robert Michel | From the Volume XVII No. 15 – October 25, 2010 Issue
CEO SUMMARY: In a pioneering collaboration, the pathology department at Beth Israel Deaconess Medical Center in Boston, Massachusetts, will work with GenomeQuest, Inc., to perform whole genome sequencing of tumor specimens. GenomeQuest will handle sequencing, assembly, and annota…
Genome Sequencing Promises to be Disruptive
By R. Lewis Dark | From the Volume XV No. 14 – October 20, 2008 Issue
EVERYONE SHOULD CAREFULLY READ OUR LEAD STORY ON THE FACING PAGE. Titled “Rapid Gene Sequencing Predicted by Mid-2009,” it is a revealing look at the declaration of California-based Complete Genetics that, in less than eight months, it will begin delivering full human genome sequ…
Rapid Genome Sequencing Predicted by Mid-2009
By Robert Michel | From the Volume XV No. 14 – October 20, 2008 Issue
CEO SUMMARY: In the same way that the Human Genome Project was disrupted by the entry of C. Craig Venter and Perkin-Elmer in what was then a 15-year, $3 billion project, now Complete Genetics of Mountain View, California, is disrupting the race to the $1,000 human genome sequence. Develop…
July 3, 2006 “Intelligence: Late Breaking Lab News”
By Robert Michel | From the Volume XIII No. 9 – July 3, 2006 Issue
Last Friday afternoon, it was announced that Siemens AG would acquire the diagnostics division of Bayer Healthcare. Siemens will pay $5.4 billion and the deal is expected to close in early 2007, subject to regulatory approval. Sales at Bayer Diagnostics totaled $1.8 …
Luminex and PerkinElmer Ink Licensing Agreement
By Robert Michel | From the Volume XIII No. 1 – January 16, 2006 Issue
CEO SUMMARY: PerkinElmer’s interest in the multiplex capabilities of Luminex’s xMap technology led to this new licensing agreement. PerkinElmer’s instrument systems played a major role in accelerating the work of the Human Genome Project. Now, besides bioresearch applications, Perki…
CURRENT ISSUE
Volume XXXI, No. 16 – November 25, 2024
Two different federal lawsuits that challenge the authority of the federal Food and Drug Administration (FDA) to regulate laboratory developed tests (LDTs) will be combined. Plaintiffs and the government in both cases agreed to move forward on this basis.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized
The Dark Report • 21806 Briarcliff Dr • Spicewood, TX 78669
Phone: 512-264-7103 • Toll Free Number: 800-560-6363
Email: info@darkreport.com
© 2024 The Dark Report. All rights reserved.